| 1 |
Analysis of shared heritability in common disorders of the brain
Verneri Anttila et al. · Science
Open access577 authors |
21 Jun 2018 |
2,056 |
| 2 |
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
Kasper Recourt, Peter de Boer, Rob G. J. A. Zuiker et al. · Translational Psychiatry
Open access |
3 Sep 2019 |
87 |
| 3 |
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
Sander Brooks, Gabriël E. Jacobs, Peter de Boer et al. · Journal of Psychopharmacology
|
15 Jan 2019 |
77 |
| 4 |
Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial
Gregory P. Strauss, Farnaz Zamani Esfahlani, Hiroki Sayama et al. · Schizophrenia Bulletin
Open access |
31 Dec 2019 |
76 |
| 5 |
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Michael H Davidson, Jay B. Saoud, Corinne Staner et al. · Schizophrenia Bulletin
Open access |
27 Jan 2022 |
63 |
| 6 |
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
Peter de Boer, Wayne Curtis Drevets, Hany Z. Rofael et al. · Journal of Psychopharmacology
|
31 May 2018 |
53 |
| 7 |
Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms
Richard S.E. Keefe, Philip D. Harvey, Anzalee Khan et al. · The Journal of Clinical Psychiatry
|
14 May 2018 |
34 |
| 8 |
Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression
Philip D. Harvey, Jay B. Saoud, R. Luthringer et al. · Schizophrenia Research
|
2 Sep 2019 |
31 |
| 9 |
The brief negative symptom scale (BNSS): Sensitivity to treatment effects
Brian W Kirkpatrick, Jay B. Saoud, Gregory P. Strauss et al. · Schizophrenia Research
|
21 Dec 2017 |
30 |
| 10 |
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis
Spyridon Siafis et al. · The Lancet Psychiatry
|
30 Nov 2023 |
24 |
| 11 |
Remote Assessment of Negative Symptoms of Schizophrenia
David Gordon Daniel, Alex S. Cohen, Dawn I. Velligan et al. · Schizophrenia Bulletin Open
Open access |
2023 |
20 |
| 12 |
Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition
Sydney H James, Anthony O. Ahmed, Philip D. Harvey et al. · European Neuropsychopharmacology
|
17 Jul 2024 |
19 |
| 13 |
Long-term effects of Roluperidone on negative symptoms of schizophrenia
Jonathan Rabinowitz, Corinne Staner, Jay B. Saoud et al. · Schizophrenia Research
Open access |
16 Mar 2023 |
19 |
| 14 |
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them
Oliver Howes et al. · American Journal of Psychiatry
Review |
8 Oct 2025 |
13 |
| 15 |
Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial
Jonathan Rabinowitz, Stefan Badescu, Pavel Palamarchuk et al. · Schizophrenia Research
|
30 Jul 2019 |
13 |
| 16 |
Depression in Heart Failure: A Systematic Review.
Waguih William Ishak, Gabriel Edwards, Nathalie Herrera et al. · PubMed
Open access |
2020 |
12 |
| 17 |
Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements
Stephen R. Marder, Michael H Davidson, Silvia Zaragoza et al. · Schizophrenia Bulletin Open
Open access |
2020 |
12 |
| 18 |
Efficacy and Safety of Seltorexant in Insomnia Disorder
Sofie Mesens, Andrew D. Krystal, Rama Melkote et al. · JAMA Psychiatry
Open access |
13 Aug 2025 |
11 |
| 19 |
Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence
Michael Davidson, William T. Carpenter · Schizophrenia Bulletin
Open access |
29 Sep 2023 |
11 |
| 20 |
Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria
Philip D. Harvey, Michael Davidson, J. Saoud et al. · Schizophrenia Research
Open access |
26 Jul 2024 |
7 |
| 21 |
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial
Matin Mortazavi et al. · CNS Drugs
Open access |
11 Sep 2025 |
5 |
| 22 |
Who has poor insight, my patient suffering from schizophrenia or myself?
Michael H Davidson, Ofer Agid · European Neuropsychopharmacology
|
12 Jan 2023 |
5 |
| 23 |
Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia
Michael H Davidson, Nadine Noël, Florent Schmitt et al. · The International Journal of Neuropsychopharmacology
Open access |
20 May 2025 |
4 |
| 24 |
Diversity in Naturally Acquired Immunity to Group B Streptococcus: A Comparative Study of Women From Bangladesh, Malawi, and the United Kingdom
Shadia Khandaker, Shilpee Sharma, Tom Hall et al. · The Journal of Infectious Diseases
Open access |
7 Dec 2024 |
3 |
| 25 |
Clinically Meaningful Improvement in the treatment of Negative Symptoms of Schizophrenia: The Case of Roluperidone
Jonathan Rabinowitz, Stefan Leucht, Michael H Davidson et al. · medRxiv
PreprintOpen access |
9 Sep 2026 |
0 |
| 26 |
Cognitive decline in psychotic disorders: A longitudinal matched case-control study
Noaz Cohen, Nomi Werbeloff, Lucian Tatsa-Laur et al. · Schizophrenia Research Cognition
Open access |
22 Aug 2026 |
0 |
| 27 |
Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE
Helene Speyer, Jonathan Rabinowitz, Remy Luthringer et al. · Schizophrenia Research
Open access |
6 Jun 2026 |
0 |
| 28 |
Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement
Armida Mucci, Michael Davidson, Sílvia Zaragoza Domingo et al. · Neuroscience Applied
Open access |
2026 |
0 |
| 29 |
Methodologic Considerations on Developing Drugs for Negative Symptoms and Cognitive Impairment in Schizophrenia
M. Davidson, J. Saoud, Rémy Luthringer · Comprehensive approach to psychiatry
Book chapter |
2025 |
0 |
| 30 |
Olanzapine added to roluperidone, in patients with schizophrenia and negative symptoms, a safety open-label trial
Michael Davidson, R. Luthringer, Jay B. Saoud et al. · Neuroscience Applied
Open access |
2024 |
0 |
| 31 |
Exposure to antipsychotic medications and risk for hip fracture: a population-based cohort study
Amir Krivoy, Dana Arnheim, A. Dotan et al. · Neuroscience Applied
Open access |
2024 |
0 |
| 32 |
Antipsychotic medications reduce the risk for prostate cancer in males with schizophrenia: a population-based, cohort study
Amir Krivoy, Dana Arnheim, A. Dotan et al. · Neuroscience Applied
Open access |
2024 |
0 |
| 33 |
Prevalence of Prominent and Predominant Negative Symptoms Across Different Criteria for Negative Symptom Severity And Clinical Stability: A Comparison of Different Criteria
Philip D. Harvey, Michael Davidson, Jay B. Saoud et al. · SSRN Electronic Journal
PreprintOpen access |
2024 |
0 |
| 34 |
Caractérisation de l’architecture du sommeil par Somno-Art Software à partir de différentes sources de signaux cardiaques et actimétriques
Laurie Thiesse, Benjamin Bleux, Rene Gebel et al. · Médecine du Sommeil
|
28 Feb 2024 |
0 |
| 35 |
Détection automatique des périodes de siestes par Somno-Art Software comparé à la Polysomnographie
Antoine Viola, Laurie Thiesse, René Gebel et al. · Médecine du Sommeil
|
28 Feb 2024 |
0 |
| 36 |
THE ROMA COMMUNITY OF ROME: HEIRS TO THE LEGACY OF A GHETTO SYSTEM
Jon Calame · Journal of Research in Architecture & Planning
Open access |
30 Dec 2010 |
0 |
| 37 |
Effet de la Paroxetine sur le sommeil de patients dépressifs analysé avec Somno-Art et la polysomnographie
Antoine Viola, Laurie Thiesse, Luc Staner et al. · Médecine du Sommeil
|
Mar 2023 |
0 |
| 38 |
Variabilité interscoreurs entre 5 centres de sommeil comparé à une analyse cardio-actimétrique
Antoine Viola, Laurie Thiesse, Luc Staner et al. · Médecine du Sommeil
|
Mar 2023 |
0 |
| 39 |
Effectiveness of oral versus long-acting antipsychotic treatment early-phase schizophrenia patients: an open-label randomized trial
Inge Winter, Michael Davidson, Wolfgang W. Fleischhacker et al. · European Psychiatry
Open access |
Jun 2022 |
0 |
| 40 |
S.09.04 New pharmacological treatments for negative symptoms: pitfalls and future perspectives of clinical trials
M. Davidson, J. Saoud, C. Staner et al. · European Neuropsychopharmacology
|
Dec 2019 |
0 |